IFM Therapeutics is a privately held biopharmaceutical company. Seeded by Atlas Venture, the company was founded in 2015 by an international group of preeminent scientists and physicians to discover and develop small molecules that modulate novel targets in the innate immune system as next generation therapies for cancer, autoimmunity, and inflammatory disorders. Drugs in the IFM portfolio are expected to significantly improve upon standard of care agents in terms of efficacy and safety.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/22/16 | $27,000,000 | Series A |
Abingworth Atlas Venture Novartis Venture Funds | undisclosed |
| 12/02/19 | $55,500,000 |
Abingworth Atlas Venture Omega Funds  | undisclosed |
